XCMG Delivers 100 All-Electric, Autonomous Mining Trucks to Yimin Mine, Pioneering Global Zero-Carbon Mining

HULUNBUIR, China, May 28, 2025 /PRNewswire/ — In a landmark achievement for sustainable mining, (“XCMG”, SHE:000425) has successfully delivered 100 units of all-electric, unmanned mining trucks to the Huaneng Yimin Open-Pit Coal Mine in Inner Mongolia, China. This milestone establishes the Yimin Mine as the world‘s first mining site to operate a fleet of 100 zero-carbon, fully autonomous electric haul trucks, marking a transformative leap in green and intelligent mining practices.

“This initiative represents a convergence of energy, technological, equipment, and commercial revolutions,” Yang Dongsheng, chairman of XCMG Group and XCMG Machinery, hailed the project as a triumph of cross-industry collaboration. “By partnering with industry leaders, XCMG has delivered a world-class blueprint for global green, intelligent mining. Starting with autonomous electric trucks, we will expand to unmanned excavators, drilling rigs, and loaders, creating a comprehensive zero-carbon, unmanned mining ecosystem.”

The world’s first fleet of 100 all-electric and autonomous mining trucks is the world‘s first integrated system combining smart battery-swapping technology, autonomous vehicle clusters, and green energy solutions. The system incorporates cutting-edge innovations such as unmanned driving, 5G connectivity, AI-powered safety management, and photovoltaic-generated electricity.

The autonomous, all electric mining trucks have achieved high-efficiency performance benchmarks:

• Extreme Weather Resilience: Operate seamlessly in temperatures as low as -40°C, supporting round-the-clock operations.
• Rapid Battery Swapping: Fully automated battery replacement in under 6 minutes.
• Superior Productivity: 120% efficiency compared to traditional manned fleets.

Annually, the 100-vehicle fleet will replace over 15,000 tons of diesel consumption and reduce CO₂ emissions by 48,000 tons, underscoring its role in combating climate change.

Li Shuxue, Chairman of Huaneng Inner Mongolia East Energy Co., Ltd., emphasized the project‘s broader significance: “This fully domestic, zero-carbon solution empowers mining with AI, enhances safety, and accelerates the industry‘s digital transformation. It is a pivotal step toward overcoming reliance on imported heavy equipment and advancing China‘s high-quality development in mining.”

XCMG remains committed to driving the future of mining through digitalization, intelligent innovation, and sustainable practices. By fostering strategic partnerships and sharing expertise, the company aims to set new global standards for smart, zero-carbon mining while contributing innovative solutions to the world.

With the launch of PFPFA HK Limited, SingWealth Holdings reinforces its commitment to regional growth and delivering seamless, high-quality financial solutions through its licensed operations in Singapore and Hong Kong SAR. 

SINGAPORE, May 28, 2025 /PRNewswire/ — SingWealth Holdings is pleased to announce its successful acquisition of an insurance brokerage licence in Hong Kong SAR, marking a significant milestone in its regional expansion. With this licence, SingWealth Holdings has established PFPFA HK Limited, further reinforcing its commitment to delivering comprehensive wealth management solutions beyond Singapore while upholding its philosophy of “Think Global, Act Local.”

To celebrate this significant expansion, a grand launch event was held today at Gonpachi Restaurant, Tsim Sha Tsui, Hong Kong. The exclusive gathering provided a valuable opportunity to connect with industry leaders and key stakeholders from SingWealth Holdings and PFPFA HK Limited, including Mr. Jeffrey Chow, Director of SingWealth Holdings, and Mr. Peter Huber, Non-Executive Chairman of SingWealth Holdings. The event also served as a platform to discuss the broader implications of SingWealth Holdings’ entry into the Hong Kong market for financial professionals and clients within the Greater Bay Area.

“Securing our insurance brokerage licence in Hong Kong is a pivotal step in SingWealth Holdings’ regional growth strategy,” said Mr. Jeffrey Chow, Director of SingWealth Holdings. “This expansion allows us to extend our expertise and provide clients in Hong Kong with seamless, high-quality wealth management solutions.”

Through PFPFA HK Limited, SingWealth will now deliver its comprehensive financial services to clients across the Greater Bay Area. This milestone reflects SingWealth Holdings’ ongoing mission to offer personalized and forward-thinking financial strategies while maintaining the highest standards of service and integrity.

About SingWealth Holdings

SingWealth Holdings is a dynamic holding company with a strategic presence across Singapore, Thailand, Malaysia, Mainland China, and Hong Kong. Through its subsidiaries, it delivers comprehensive financial advisory, insurance brokerage, and estate planning solutions tailored to the evolving needs of individuals and businesses.

Its financial services portfolio comprises PFPFA Pte Ltd (Singapore) and PFPFA HK Ltd (Hong Kong), providing trusted financial expertise and strategic advisory solutions to clients in their respective markets.

SingWealth Holdings also supports PFP Legacy entities across the region, catering to the needs of emerging affluent clients with wills and trust services in Singapore, Thailand, Malaysia, Hong Kong, and Shanghai. These services are designed to safeguard wealth and ensure smooth succession planning for individuals and families.

In Singapore, SingWealth Holdings operates Assure Healthcare Holdings, a healthcare brand committed to accessible, patient-centered care. Assure Healthcare offers general practitioner services, preventive medical care, aesthetic treatments, and Advance Medical Directive (AMD) support.

Driven by innovation and excellence, SingWealth Holdings continues to empower communities across Asia with financial stability and enhanced well-being.

For more information, visit https://singwealthholdings.com 

GOLD COAST, Australia, May 28, 2025 /PRNewswire/ — Australian family-owned and operated, Biosota Organics has officially gone Hollywood. The brand’s award-winning high MGO-rated Manuka honey was featured in the highly anticipated 2025 Hollywood Moms Mother’s Day Gift Bag, curated by the legendary Distinctive Assets—renowned for assembling luxury gift experiences for the GRAMMYs®, Oscars®, and today’s most influential celebrities.

The curated gift set includes Biosota’s signature MGO 2200+ Manuka honey, a luxurious, high-potency jar that has already earned multiple international awards retailing for $1,033 for a 500g jar. It’s one of the most powerful honeys available globally, and now it’s earning a spot in medicine cabinets and kitchen pantries of Hollywood’s A-list moms.

Celebrity moms receiving the gift include Jennifer Lawrence, Olivia Munn, Mindy Kaling, Priyanka Chopra, Megan Fox, Kaley Cuoco, Holly Robinson Peete and Elisabeth Rohm, among others.

While garnering fame among Hollywood’s elite, Biosota stays true to its roots—delivering natural, evidence-based Manuka honey solutions for families everywhere, with a range of products to suit every need and budget.

“We’re thrilled to see Biosota included in this iconic gift collection,” said Andrey Zubko, CEO of Biosota Organics. “This isn’t just honey—it’s a medicinal-grade superfood with benefits that go far beyond the spoon. From immune support to wound care and daily wellness, our honey is the result of three generations of beekeeping expertise paired with the pristine environment of Australia’s native bushland.”

Biosota’s premium Manuka honey is available online at www.biosota.com.au and www.biosota.com/en-us (USA), with fast shipping and no duties for North American customers.

About Biosota Organics
Biosota Organics is an Australian family business producing high-grade, certified organic Manuka honey. Known for its exceptional MGO ratings and therapeutic properties, Biosota’s honey is trusted by customers worldwide for its quality, purity and potency.

PROVIDENCE, R.I., May 28, 2025 /PRNewswire/ — EpiVax, Inc., a leader in preclinical immunogenicity assessment for biologic therapeutics and vaccines, is pleased to announce the appointment of Vibha Jawa, PhD, FAAPS as Chief Scientific Officer. Dr. Jawa succeeds EpiVax founder and Executive Chairwoman Annie De Groot, MD, who has transitioned from CSO to Chief Medical Officer. 

Dr. Jawa brings over two decades of leadership in biologics, vaccine, and gene therapy development and immunogenicity strategy to EpiVax. Most recently, she served as Executive Director of Translational Medicine at Bristol Myers Squibb, where she led bioanalytical strategy, supporting PK- and immunogenicity-related preclinical and clinical assessments across the development pipeline. She has held senior roles at Merck and Amgen where she led immunogenicity assessment efforts, supporting discovery to development. Dr. Jawa has contributed to more than 20 successful IND, BLA, and MAA filings across many therapeutic modalities, and was part of the team at the Institute of Human Gene Therapy (UPENN) that supported the first approved gene therapy product.

A recognized thought leader in bioanalysis and immunogenicity from discovery through commercialization, Dr. Jawa has authored over 100 peer-reviewed publications and holds prominent roles in various renowned scientific societies and consortiums, including AAPS, IQ, SC, and EIP. She was named an AAPS fellow in 2022 for her significant contributions. 

“We’re thrilled to welcome Vibha to the team,” said Dr. Rich-Henry Schabowsky, CEO of EpiVax. “Her depth of experience in biologics, especially novel modalities, combined with her expertise in evaluating and mitigating immunogenic risk will be instrumental as we continue evolving our methods to meet the complex needs of the industry.”

Dr. Annie De Groot, EpiVax co-founder and CMO, added: “Dr. Jawa is the perfect scientific leader for EpiVax 2.0: the transformation of our company that began in 2024. She brings the exact energy that EpiVax needs at this juncture. I’m thrilled to be handing the baton to Dr. Jawa, who will ensure that EpiVax remains at the cutting edge of immunogenicity science— pushing boundaries, validating new ideas, building bridges between in vitro data, immunoinformatics and AI, and setting higher standards for translational immunology.”

Dr. Jawa will have outward and inward facing responsibilities as CSO. She will represent EpiVax at key meetings, while leading internal research and validation efforts. Her leadership will help expand the company’s reach into new therapeutic areas and reinforce EpiVax as a trusted partner in biologic and vaccine development.

“I’m thrilled to be joining the EpiVax team,” said Dr. Jawa. “This is an extraordinary company with a long history of scientific leadership in immunogenicity assessment. I look forward to building on that legacy and continuing to refine the team’s approaches, ensuring that we deliver the most accurate, insightful support.”

About EpiVax: EpiVax is a leader in preclinical immunogenicity assessment and sequence optimization for peptide therapeutics, biologic therapeutics, gene/cell therapies, and vaccines. EpiVax partners with a global roster of companies, agencies, and academics to accelerate immunogenicity risk assessment, immune modulation, and rapid vaccine design. EpiVax.com

Press Contact:
Sarah Moniz
Smoniz@epivax.com